Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Canada
  4. Toronto Stock Exchange
  5. Knight Therapeutics Inc.
  6. News
  7. Summary
    GUD   CA4990531069

KNIGHT THERAPEUTICS INC.

(GUD)
  Report
Delayed Toronto Stock Exchange  -  04:00 2022-12-02 pm EST
5.460 CAD   +2.06%
12/01Knight Therapeutics Relaunches Akynzeo in Canada
MT
12/01Knight Therapeutics Brief: Announcing Relaunch of AKYNZEO in Canada
MT
12/01Knight Announces Relaunch of AKYNZEO« in Canada
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

National Bank Maintains 'Positive View' of Knight Therapeutics Following Investor Meetings

09/30/2022 | 11:26am EST


ę MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
EXELON CORPORATION -0.19% 41.45 Delayed Quote.1.35%
GUD HOLDINGS LIMITED -0.24% 8.2 Delayed Quote.-27.88%
KNIGHT THERAPEUTICS INC. 2.06% 5.46 Delayed Quote.3.02%
All news about KNIGHT THERAPEUTICS INC.
12/01Knight Therapeutics Relaunches Akynzeo in Canada
MT
12/01Knight Therapeutics Brief: Announcing Relaunch of AKYNZEO in C..
MT
12/01Knight Announces Relaunch of AKYNZEO« in Canada
GL
12/01Knight Therapeutics Inc. Announces Relaunch of AKYNZEO in Canada
CI
11/10Transcript : Knight Therapeutics Inc., Q3 2022 Earnings Call, Nov 10, 2022
CI
11/10Tranche Update on Knight Therapeutics Inc.'s Equity Buyback Plan announced on July 12, ..
CI
11/10Knight Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months..
CI
11/10Knight Therapeutics Inc. Updates Revenue Guidance for Fiscal 2022
CI
11/10Earnings Flash (GUD.TO) KNIGHT THERAPEUTICS Reports Q3 Revenue C$72.281 Million
MT
11/10Knight Therapeutics Reports Third Quarter 2022 Results
GL
More news
Analyst Recommendations on KNIGHT THERAPEUTICS INC.
More recommendations
Financials
Sales 2022 275 M 204 M 204 M
Net income 2022 -22,5 M -16,7 M -16,7 M
Net Debt 2022 - - -
P/E ratio 2022 -28,7x
Yield 2022 -
Capitalization 618 M 459 M 459 M
Capi. / Sales 2022 2,25x
Capi. / Sales 2023 2,04x
Nbr of Employees 660
Free-Float 69,6%
Chart KNIGHT THERAPEUTICS INC.
Duration : Period :
Knight Therapeutics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KNIGHT THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 5,46 CAD
Average target price 7,09 CAD
Spread / Average Target 29,8%
EPS Revisions
Managers and Directors
Samira Sakhia President, Chief Executive Officer & Director
Utchanah Arvind Chief Financial Officer
Jonathan Ross Goodman Executive Chairman
Monica Percario Vice President-Global Scientific Affairs
Daniela Marino Marino Vice President-Legal and Compliance
Sector and Competitors